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Abstract
Prostate cancer (PCa) is the most common non-cutaneous cancer in male subjects and the
second leading cause of cancer-related death in developed countries. The necessity of a
non-invasive technique for the diagnosis of PCa in early stage has grown through years.
Proton magnetic resonance spectroscopy (1H-MRS) and proton magnetic resonance spec-
troscopy imaging (1H-MRSI) are advanced magnetic resonance techniques that can mark
the presence of metabolites such as citrate, choline, creatine and polyamines in a selected
voxel, or in an array of voxels (in MRSI) inside prostatic tissue. Abundance or lack of these
metabolites can discriminate between pathological and healthy tissue. Although the use of
magnetic resonance spectroscopy (MRS) is well established in brain and liver with dedi-
cated software for spectral analysis, quantification of metabolites in prostate can be very dif-
ficult to achieve, due to poor signal to noise ratio and strong J-coupling of the citrate. The
aim of this work is to develop a software prototype for automatic quantification of citrate,
choline and creatine in prostate. Its core is an original fitting routine that makes use of a
fixed step gradient descent minimization algorithm (FSGD) and MRS simulations developed
with the GAMMA libraries in C++. The accurate simulation of the citrate spin systems allows
to predict the correct J-modulation under different NMR sequences and under different cou-
pling parameters. The accuracy of the quantifications was tested on measurements per-
formed on a Philips Ingenia 3T scanner using homemade phantoms. Some acquisitions in
healthy volunteers have been also carried out to test the software performance in vivo.
Introduction
Prostate cancer (PCa) is the most common cancer in men, and the second leading cause of
cancer-related death in developed countries [1]. Traditionally, PCa detection and local staging
depend on a combination of different tests, such as serum prostate-specific antigen (PSA) and
digital rectal examination (DRE) [2,3]. Correct assessment of the tumor stage is crucial for
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disease management. In vivo magnetic resonance techniques (1H-MRS and 1H-MRSI) have
been proved to be suitable noninvasive methods both to aid accurate detection of PCa [4,5]
and to improve the definition of tumor extent [3] because metabolic alteration represents an
hallmark of cancer [6]. High Resolution Magic Angle Spinning Magnetic Resonance Spectros-
copy (HR-MAS) is a powerful tool that provides magnetic resonance spectra of ex vivo sample
[6,7]. HR-MAS is an high field Nuclear Magnetic Resonance (NMR). It allows to obtain high
resolution spectra, and for this reason many more metabolites are detectable with respect to in
vivo 1H-MRS [6,7], providing a survey about PCa metabolomics. Ex vivo (HR-MAS) and in
vivo (1H-MRS) studies show that metabolites, such as citrate (Cit), choline (Cho), creatine (Cr)
and even polyamines are related with PCa [8–11], furthermore their concentrations have a
good sensitivity and specificity for the diagnosis of PCa [12–15]. In particular the ratios
between their concentrations, i.e. (Cho+Cr)/Cit or Cho/Cit, are the variables of greatest clini-
cal interest because of their correlation with the Gleason score [16]. Although the use of
1H-MRS to study metabolic changes in brain and liver tumors is well established and sup-
ported by the use of recognized research software (jMRUI [17], LCMODEL [18], and Tarquin
[19]), the same is not true for PCa. The absence of a dedicated software for the prostate MRS
signal analysis makes quantification not well suited for clinical practice, although some
commercial software (i.e. jMRUI [20] and LCMODEL [21]) provide features and tools for sim-
ulation that fit the purpose. The main problem in quantitative prostate MRS is citrate quantifi-
cation. Cit spectrum shows a strong J-coupling modulation dependent on pulse sequence
parameters, especially on the echo time (TE) [22]. In order to take account of the coupling and
properly quantify citrate, the spectrum has to be simulated in the same condition of pulse
sequences. In this work, simulations of spectra were performed with a C++ package that uses
density matrix formalism [23] to calculate the evolution of the magnetization under different
pulse sequences. The aim of this work is the development of a homemade software that allows
the automatic analysis of the MRS signals based on spectra simulations.
Materials and Methods
Phantom measurements
In order to calibrate and assess homemade software quantification ability, six phantoms
(250-ml polyethylene bottles) were prepared with the solutions reported in Table 1, following
the method used by Garcı´a-Martı´n et al. [21]. All of them were filled with 250 ml distilled
water containing 155 mM NaCl, and prepared at pH = 7. Only one phantom (n˚6 in Table 1)
was prepared at pH = 5, to identify possible changes in Cit spectrum due to pH variability (this
phantom was not included in the quantification test). HCl and NaOH were used to regulate
the pH. All the pH measurements were performed with Cyberscan 500 (Eutech Instruments)
pH meter. Some metabolites contain acid or basic chemical groups and so, in solution, pH
value determines whereas hydrogen nuclei are associated or not with acid (or basic) groups,
affecting proton chemical shift values and J-modulation [24]. Choline chloride (98%, C7527
Sigma-Aldrich, St. Louis, MO, USA), sodium citrate dehydrate (99%, W302600 Sigma-
Aldrich, St. Louis, MO, USA) and creatine monohydrate (98%, C3630 Sigma-Aldrich,
St. Louis, MO, USA), were used respectively as Cho, Cit and Cr source. Concentrations of
metabolites, NaCl and pH in phantoms were chosen also considering the work of Kavanagh
et al. [25] to resemble physiological values. Paramagnetic salts were not used in phantoms.
MR spectroscopy acquisitions were performed on a 3T MR scanner (Ingenia, Philips Health-
care, Best, The Netherlands) equipped with “Whole Body Transmitter Coil” incorporated
into the bore (no external transmitter coils). “Ingenia Philips 3T Scanner Receiver Head Coil”
(30 cm coverage, 15 channels, direct digital data sampling) was used for all the phantom
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measurements. Single voxel spectra (SVS) relative to phantom data were collected by means of
Point Resolved Spectroscopy Sequences (PRESS) with three Chemical Shift Selective (CHESS)
pulses for water suppression and a relatively long repetition time (TR). PRESS parameters
were: TR/TE = 3000/140 ms, voxel size of 2×2×2.5 cm3 (positioned in the center of the phan-
toms), 1.2 cm slice thickness, 1024 points in resolution, 2000 Hz bandwidth (512 ms acquisi-
tion time), and 192 averages. PRESS was chosen because it has a better Signal to Noise Ratio
(SNR) than the Stimulated Echo Acquisition Mode sequence (STEAM) [26].
In vivo measurements
In order to test the fitting ability of the homemade software, in vivo spectra were acquired
from two healthy volunteers. The volunteers signed appropriate informed consent and the
study was approved by the institute ethic committee (“Comitato Etico IRST IRCCS-AVR”).
The hardware was the same as for phantom acquisitions with the exception of the receiver coil,
which was an Anterior Phased Array Coil (PAC) having 100 cm coverage, 52 channels and
direct digital data sampling. From the first healthy volunteer, a single-voxel scan and a 3D
PRESS (1H-MRSI) with 1024 points in resolution were acquired, while from the second volun-
teer only a 3D PRESS with 2048 points was acquired. In both cases, a 2000 Hz bandwidth (512
ms acquisition time) was used. The sequences were launched with TE = 140 ms (to see peaks
of Cit approximately in-phase) and TR = 1500 ms. For ethical reasons, volunteers were not
subjected to the standard preparation protocol. In particular, anticholinergics were not admin-
istered to diminish rectum movements. Number of averaged signals was reduced from 192 to
32 to achieve a shorter exam time (at the expense of SNR), while Specific Absorption Rate
(SAR) and Peripheral Nerve Stimulation (PNS) modes were set to “low”. For the two healthy
volunteers, five slices of 1.2 cm in thickness were acquired; in each slice there was a matrix of
9×7 voxels of 1×1×1.2 cm3 of volume (for a total of 315 spectra). Voxel size in single-voxel
scan was 1.5×1.5×1.5 cm3 and the voxel was placed in the peripheral zone of the prostate
gland. In the single-voxel spectrum acquisition three CHESS pulses were used for water sup-
pression, while for 3D PRESS spectra acquisitions dual bandwidth Basing Pulse [27] to water
and fat suppression were used instead.
Software and data processing
Spectroscopic data were analyzed by means of a homemade software, based on GAMMA C+
+ libraries [28] and on a gradient descent algorithm [29], running on Linux operating system.
To avoid the divergence of the gradient during the iterative process, a fixed step approach like
the one used in digital signal processing (FSGD) [30] was used. It allows the parameters to
change only by fixed quantities, following the sign of the gradient but ignoring its magnitude.
Before the iterative fitting process starts, all the in vivo spectra are smoothed with an automatic
apodization of 2 Hz. No smoothing was used for phantoms, since the SNR was already
Table 1. Composition of the homemade phantoms.
n˚ Cit (mM) Cho (mM) Cr (mM) NaCl (mM) pH
1 5.0 ± 0.1 20.0 ± 0.2 16.1 ± 0.2 155 ± 1 7.00 ± 0.05
2 15.0 ± 0.1 15.0 ± 0.2 12.1 ± 0.2 155 ± 1 7.00 ± 0.05
3 25.0 ± 0.2 10.0 ± 0.2 9.4 ± 0.2 155 ± 1 7.00 ± 0.05
4 40.0 ± 0.3 7.5 ± 0.2 7.5 ± 0.1 155 ± 1 7.00 ± 0.05
5 60.0 ± 0.5 5.0 ± 0.1 5.4 ± 0.1 155 ± 1 7.00 ± 0.05
6 60.0 ± 0.5 0 0 155 ± 1 5.00 ± 0.05
doi:10.1371/journal.pone.0165730.t001
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acceptable. A detailed explanation of the principal functions used by the software is provided
in the Appendix, while a block diagram of the software algorithm is shown in Fig 1.
GAMMA package for MRS simulations is based on density matrix formalism to make pre-
visions about NMR spectra after a RF pulse sequence is applied. Density matrix formalism is
an useful tool to describe the behavior of strong-coupled spins systems, such as the hydroge-
nous nuclei in the two equivalent methylene groups of Cit [21, 23]. In order to simulate the
spin systems, the software requires a text file (“Spin system knowledge” block in Fig 1) contain-
ing the NMR properties of each metabolite (i.e. the isotope type, frequencies for each proton
in the metabolite, the scalar coupling between each proton couple and the spectrometer fre-
quency). All the NMR parameters were measured from the spectra both for in vitro and in vivo
quantifications (see the Appendix for more details). The acquisition parameters used for the
specific NMR sequence (i.e. TE in pulse sequence, sampling time and resolution) are given as
input through a graphical user interface. The free induction decay (FID) signal of an ideal
PRESS sequence is simulated for each metabolite by means of the GAMMA methods. The soft-
ware Fourier transforms the simulated FIDs and computes the weighted sum of the metabo-
lites simulated spectra using an appropriate model and initial set of parameters (see appendix).
Afterwards, the software compares the model spectrum to the measured one using a cost func-
tion. Finally, it updates the parameters and proceeds to the next iteration minimizing the cost
function. The iterative process takes a defined number of steps (900 steps were selected for the
purpose). When the iterative process terminates, the software gives back the optimized simu-
lated spectrum together with the output parameters of the simulated metabolites (amplitude,
relative frequency, relative phase, etc.). Since the software is able to define the spectrum of
each metabolite (see appendix and Fig 1), it is possible calculate the area (or integral) of each
metabolite. Areas are calculated by summing the simulated points of the metabolite spectra
on the whole frequency interval (i.e. the selected 2000 Hz in bandwidth). For comparison,
spectra quantifications were performed also using AMARES algorithm (in jMRUI software).
AMARES deconvolves a sampled FID in a series of exponentially damped sinusoids [31].
AMARES peak parameters were determined using the “peak picking” function with no prior
knowledge. Furthermore, jMRUI software provides also a package, (named QUEST [32]) able
to quantify spectra using simulated FIDs. The simulated basis set can be built using NMRsco-
peB [33], a simulation tool included in the jMRUI package. QUEST algorithm was used in the
comparative analysis too. The metabolite basis set was created using NMRscopeB, Cit was
modeled with the same parameters used for the homemade software analysis, while chemical
shift and multiplicities of Cho and Cr where chosen to produce single peaks at frequencies of
3.27 ppm (Cho) and two peaks at 3.0 and 3.9 ppm (Cr).
Statistical analysis
In order to assess the goodness of the fit, the Kolmogorov-Smirnov test (K-S Test) [29] was
used in every quantification, comparing the simulated spectrum with the acquired one in the
interval comprised between 2.1 and 3.6 ppm, which is the one where the principal peaks of the
metabolites can be identified. K-S test was performed using the Matlab function “kstest2”. This
function takes as input the simulated and measured spectra, and returns a test decision for the
null hypothesis (i.e. the spectra come from the same continuous distribution), giving p and D
values of K-S test. In this test, the D value is the maximum difference between the cumulative
distributions (integral of the spectra) and p-value is the probability that to reject the null
hypothesis is a mistake. If p value is high (greater than 0.05) there is not enough evidence to
reject the null hypothesis. Metabolite quantifications were also performed using jMRUI soft-
ware [17], in order to test the performances of the homemade software in comparison to a
MR Spectroscopy in Diagnostic Oncology
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Fig 1. Block diagram of the homemade software for MRS signal analysis.
doi:10.1371/journal.pone.0165730.g001
MR Spectroscopy in Diagnostic Oncology
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commercial one. The agreement of the metabolites ratios, calculated using both homemade
software and AMARES [31] algorithm (in jMRUI), in comparison to the real concentration
ratios was estimated in terms of r2 coefficients. Finally K-S test was made also to compare
AMARES calculated spectra and the measured ones in the same interval (i.e. 2.1–3.6 ppm).
Results
Fig 2a–2e shows a comparison between the acquired and the simulated spectra for all phan-
toms considered in this study. The horizontal axis reports the frequency interval where only
metabolite peaks are visible and no water residual signal is present. In the same plots, the abso-
lute difference between the two spectra (measured and simulated) is also shown. In Table 2 are
summarized the results of the K-S test for the AMARES and the homemade software. At first
instance, the homemade software reproduced the metabolites spectra correctly in each phan-
tom: the identity between the measured and simulated spectra is not refutable by K-S test.
However, it is refutable in all phantom quantification except the number 2 for the AMARES
algorithm.
In phantoms, we found a good linear positive correlation between amplitudes (or area) of
the metabolites estimated by software, and the real metabolite concentration (Fig 3a–3c). For
example, the linear correlation between Cit amplitude vs Cit concentration has r2 coefficient
of 0.9997 using the homemade software (Fig 3a). An excellent linear correlation between (Cho
+Cr)/Cit concentration ratios and the same ratios estimated by software (Fig 3d) confirms the
Fig 2. Comparison between acquired smoothed (green lines) and simulated (red lines) spectra, together with their absolute difference (blue lines), for
the phantoms considered in the study and reported in Table 1: phantom a) n˚1, b) n˚2, c) n˚3, d) n˚4 and e) n˚5. f) An example of the output file of the
homemade software with the final simulation parameters obtained for phantom n˚4.
doi:10.1371/journal.pone.0165730.g002
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accuracy of the quantification, both using metabolite amplitude ratios and metabolite area
ratios. Table 3 summarizes the quantification results showing (Cho+Cr)/Cit ratios estimated
by homemade software in comparison to the real concentration ratios. Uncertainties on the
estimated ratios are only lower bounds of the real uncertainties and are produced mainly from
measuring T2 decay constants (see appendix for more information), while uncertainties in real
concentration ratios are due to precision of the balance with which metabolites were weighed.
In Fig 4, the results of metabolite amplitudes versus metabolite phantom concentrations
obtained by means of the AMARES algorithm are shown, and in Table 3 the amplitude ratios
estimated by AMARES software together the concentration ratios (Cho+Cr)/Cit are summa-
rized. Even if AMARES algorithm gave a good linear relationship between the metabolite
amplitudes and their concentrations, comparable to the ones obtained by the homemade soft-
ware (Fig 4), it provides (Fig 4d) poor agreement with the real concentration ratios of metabo-
lites inside the phantoms compared to the homemade software (Fig 3d and Table 3). QUEST
Table 2. Kolmogorov-Smirnov analysis in phantom spectra using AMARES and homemade software.
The number referring the phantom is the same of Table 1.
AMARES homemade software
n˚ p-value D-value n˚ p-value D-value
1 0.0494 0.1786 1 0.9975 0.0602
2 0.4149 0.1161 2 0.9975 0.0602
3 0.015 0.2054 3 0.9972 0.0602
4 0.015 0.2054 4 0.9973 0.0602
5 0.015 0.2054 5 0.9975 0.0602
doi:10.1371/journal.pone.0165730.t002
Fig 3. Results of the homemade software relative to the metabolite spectra amplitudes versus their concentrations for a) Cit, b) Cho and c) Cr in
phantoms. d) (Cho+Cr)/Cit estimated ratios versus real concentration ratios in phantoms.
doi:10.1371/journal.pone.0165730.g003
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routine was also tested but the overall results were meaningless, that is the algorithm was not
able to fit some of the metabolites inside phantoms in every quantification: in spectra with
“high” Cit concentration (e.g. phantom n˚5), QUEST did not measure Cho and Cr, while in
the other ones it was not able to measure Cit. The quantifications were repeated several times
varying the simulation parameters, but the results were the same. Thus, QUEST analysis
results are not shown here.
In Fig 5 in vivo spectra of the two volunteers are shown. Only a small apodization of 2 Hz
was performed on the acquired signals.
Discussion
The main aim of this work was to propose a new strategy to quantify prostate metabolites by
MRS to improve the power of non-invasive diagnostics for PCa. The motivation that brought
to the development of this tool was the absence of a dedicated routine for metabolite quantifi-
cation in prostate especially for Cit. Indeed Cit has a strong J-modulation that makes its spec-
trum shape dependent on pulse sequences parameters and environmental conditions. This
purpose was obtained by performing a rigorous quantum mechanical simulation of the hydro-
gen nuclei in the two equivalent methylene groups of Cit using the GAMMA C++ libraries.
The next problem was to find an appropriate cost function and a robust minimization algo-
rithm. As it is shown in the appendix, the sum on the frequency space of the squared differ-
ences between the absolute values of the simulated and acquired spectrum was chosen as a cost
function. The absolute value allows to ignore the global phase of the spectrum (while the rela-
tive phases are still considered) and makes the optimization less sensitive to local minima.
FSGD was used to minimize the cost function, since it provides a simple minimization tool
that ensures the convergence of the iteration process. The homemade software was firstly
tested on phantoms made in our institute. Some studies have been performed to understand
the biochemical environment of the prostate using ultra high field NMR spectroscopy [34];
these results can guide the experimenter in building up phantoms with chemical composition
similar to human prostate. Because the goal of the study was only to test the homemade soft-
ware, simple phantoms with only Cho, Cit and Cr were used, controlling the pH by addition
of diluted HCl or NaOH solutions. Control of the pH in phantom is essential because chemical
shifts and thus J-modulations are pH dependent. Significant differences in the coupling con-
stant of Cit were not observed by changing the pH of the solution (from pH 7 to pH 5); con-
versely, different line-shapes and different values of chemical shifts of Cit protons were
observed. An estimation in phantoms of chemical shifts and J-coupling value of Cit was done
by measuring the differences between frequencies of peaks in Cit spectrum, using a short TE
STEAM sequence (see appendix).
Because of the uncertainties of the estimated parameters (due to the resolution and field uni-
formity of a clinical MR scanner), the choice of J-coupling constants and Larmor frequencies
Table 3. (Cho+Cr)/Cit values estimated by homemade software (Amplitude and Area) are compared with the (Cho+Cr)/Cit values estimated by
AMARES (jMRUI software) and the same real metabolites ratios inside phantoms.
Concentration Amplitude Area Amplitude (AMARES)
7.2 ± 0.1 7.2 ± 0.2 7.2 ± 0.2 11.2 ± 0.3
1.83 ± 0.02 2.04 ± 0.05 1.77 ± 0.05 5.1 ± 0.1
0.80 ± 0.01 0.85 ± 0.03 0.76 ± 0.03 2.1 ± 0.1
0.375 ± 0.006 0.44 ± 0.03 0.39 ± 0.03 1.08 ± 0.03
0.167 ± 0.004 0.23 ± 0.03 0.20 ± 0.03 0.52 ± 0.01
doi:10.1371/journal.pone.0165730.t003
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for simulations was not univocal. PRESS sequences with long TR using different TE were used
to measure (in phantom) the relaxation time (T2
m) of the metabolites. Homemade software
and jMRUI were used to measure metabolites amplitude (and spectral area) as function of TE
to derive (from exponential fit) the T2
m relaxation values. These were measured to determine
the correction factors required to compensate the transverse relaxation processes in metabolite
quantifications (see appendix).
Consequently, the software ability to quantify the MR spectra was tested. A strong correla-
tion between metabolite concentrations and amplitudes (or areas) estimated by homemade
software was found, confirming the reliability of the model used to represent the molecules.
The goodness of the quantifications was certainly due to the correct modeling of Cit spectrum,
achieved by taking into account the J-modulation during the simulations with GAMMA. An
analogue analysis was performed using a commercial software (AMARES algorithm of jMRUI
software) but weaker correlations were found (in terms of r2 coefficients), and the estimated
(Cho+Cr)/Cit ratios were not in agreement with the real ratio calculated by molar concentra-
tions in the phantoms. This happens because metabolite peak selection performed by
AMARES is quite ill-posed for multiplets like Cit, since AMARES doesn’t take into account J-
modulation.
K-S test analysis was used both for the spectra calculated by homemade software and for
the ones calculated by AMARES. For the homemade software, p-values obtained through the
K-S test are always much higher than the critical level (0.05), implying that the null hypothe-
sis can never be rejected. Conversely using AMARES in all the quantifications (except for
phantom n˚2), the null hypothesis can always be rejected. In scientific literature, LCMODEL
is also used for quantitative MRS in the prostate [15, 21]. Unfortunately, the prostate basis
Fig 4. Results of the AMARES (jMRUI software) relative to the metabolite spectra amplitudes versus their concentrations for a) Cit, b) Cho and c) Cr in
phantoms. d) (Cho+Cr)/Cit estimated ratios versus real ratio concentrations in phantoms.
doi:10.1371/journal.pone.0165730.g004
MR Spectroscopy in Diagnostic Oncology
PLOS ONE | DOI:10.1371/journal.pone.0165730 November 10, 2016 9 / 18
set for LCMODEL is only available to the developer of this software and for an exclusive
group of research centers. However, our software provided performances comparable to the
ones obtained by using LCMODEL. Indeed it resulted that the correlation between ampli-
tude of Cit vs Cit concentration in phantoms had r2 coefficient of 0.9997 using the home-
made software, and of 0.986 in Garcia-Martin paper [21], in which LCMODEL was used for
the quantification.
The last part of this work concerned in vivo tests on healthy volunteers. In vivo acquisitions
were performed to test the ability of our algorithms to fit spectra in low SNR condition inside
the prostatic tissue. The presence of ions and the different magnetic susceptibility between
phantom and tissue could change dramatically the shape of the spectra, particularly Cit spec-
trum. This is because J-couplings and chemical shifts strongly depend on cations concentra-
tions and pH [24] (for example, cations like Zn++ or Ca++ were not present in phantoms and
also pH could be different between phantoms and prostate). Hence, a test about the ability of
the software to fit in vivo spectra had to be made. Two 3D PRESS and a single-voxel scan were
acquired from two subjects. At first, an estimation of the spectral parameters was performed as
in phantom tests, to find a range of input simulation values for in vivo Cit (J-coupling and
chemical shifts). Subsequently, the fitting ability of the homemade software was tested on com-
mon prostate spectra with low SNR. It was found that the routine was able to fit the line-shapes
of Cit (given the right NMR parameters) also for in vivo conditions.
Although in vivo quantification was not the main purpose of this work (at least in this early
stage), in Fig 5 of the manuscript there is the output file relative to a quantification performed
in the central zone of the prostate of subject 2. The values found for the ratio (Cho+Cr)/Cit
were 0.333 with amplitudes and 0.382 with integrals. Basharat et al. [20] obtained 0.4125 in the
Fig 5. In vivo spectra comparison between acquired smoothed (green lines) and homemade software simulated (red lines) spectra,
together with their absolute difference (blue lines). a) Single voxel spectrum of the peripheral zone of the prostate (Voxel size: 1.5⨯1.5⨯1.5 cm3,
1024 pts in resolution), b-c) two spectra taken from 3-D PRESS of subject 1 with 1024 pts in resolution, d-e) two spectra taken from 3-D PRESS of
subject 2 with 2048 pts in resolution, f) output of the quantification of the spectrum d).
doi:10.1371/journal.pone.0165730.g005
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central zone for the same ratio. Although the values obtained in this paper and in Basharat
look similar, it is not possible to affirm that they are in agreement because a more accurate
error handling should be made. Furthermore the prostate concentration ratio in healthy sub-
ject has a statistical variance that cannot deduced by limited cohort of subjects used for in vivo
tests.
The measurements for this work were performed on the Philips Ingenia 3T using phased
array coils (PAC); an interesting issue is the comparison between PAC and endorectal coil
(ERC) performances. Several papers have been published that compare receiver PAC with the
more invasive ERC [16, 35,36]. Particularly, the use of ERC significantly improves spectral line
width; however, good performances are obtained using PAC too. Therefore, the use of the
external PAC may be recommended for patients with rectal diseases or patients who could not
tolerate the discomfort of ERC insertion. ROC curve for cancer diagnosis based on MRS,
obtained by using ERC, has an AUC (area under curve) very similar to the one obtained by
using PAC (0.869 ERC vs 0.859 PAC) [35].
Conclusion
Quantification of the citrate is one of the main problems concerning prostate MRS. The use of
a structural NMR tool like GAMMA, associated with an optimization routine for amplitudes,
frequency shifts, relative phases and effective decay constants allows to get reliable metabolite
quantifications in prostatic tissue. In general, this approach could work well with all kinds of
NMR spectra in metabolomics. The first results relative to our quantification routine are cer-
tainly encouraging but further tests are required to assess if this kind of strategy could help the
non-invasive diagnosis of PCa at an early stage. The homemade software developed in this
study produced better results (in terms of quantification and fitting capabilities) compared to
the commercial one for all the phantom measurements. Furthermore, it showed good fitting
capabilities in vivo, also in low SNR conditions. To improve the accuracy of in vivo measure-
ments, our future purposes are mainly focused on considering polyamines quantification.
Polyamines spectra commonly overlap to creatine and choline ones, thus creating errors and
misunderstandings in MRS quantifications. Certainly to insert polyamines in the analysis will
provide an improvement in prostate MRS spectra quantification.
Appendix
Algorithm description
A block diagram of the homemade software is shown in Fig 1. The software requires the NMR
properties of the significant hydrogen groups of each metabolite (i.e. isotope type, metabolite
proton frequencies, their multiplicity, scalar coupling between each proton couple and spec-
trometer frequency) as input, together with the NMR sequence parameters (i.e. TE, bandwidth
and spectral resolution of the PRESS sequence used for acquisition). Using these input param-
eters, the software simulates Free Induction Decay (FID) signals FID(tk)
m of each metabolite
(one molecule) at a sampled time point tk, being m the metabolite index. FIDs are shifted in
frequency by an oscillating function eiΔωmtk (Δωm is the frequency shift of the mth metabolite)
and multiplied by a damped exponential in time-domain, in order to take into account the
metabolite effective transverse relaxation (T2
m). Hence, the simulated signal can be written
as:
Fmk ¼ FIDðtkÞ
me
 
tk
Tm
2 eiDomtk ðA1Þ
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Successively, the complex spectrum of a single metabolite is obtained through Fast Fourier
Transform (FFT) of its simulated signal Eq (A1):
Smk ¼ FFTðF
m
k Þ ðA2Þ
The absolute value of the simulated spectrum of all the metabolites is computed as:
jStotl ðnkÞj ¼ j
X3
m¼1
Smk ame
iφm j þ c0 þ c1nk þ c2n
2
k þ c3n
3
k þ c4n
4
k ðA3Þ
Here νk is the sampled spectrum frequency, φm its relative phase, the c0. . .c4 are the coeffi-
cients of the polynomial baseline and am is the amplitude of the metabolite signal. The
subscript l stands for the current iteration number in the computation process. Starting
parameters (i.e. amplitude, phase, etc.) for the simulation are obtained at the beginning of
every quantification by a rough grid search performed by the program.
Once the simulated spectrum is computed, the software compares it iteratively with the
acquired one, minimizing the cost function expressed as:
Costl ¼
X
k
ðjStotl ðnkÞj   jS
acqðnkÞjÞ
2
ðA4Þ
It considers the sum of the squared difference between the absolute values of the two spectra
over the selected frequency interval. Spline interpolation was used to avoid binning errors in
the computation of the cost function: the differences between the two spectra were evaluated
by oversampling them on a number of points set as:
3ðnk;Max   nk;minÞ=R ðA5Þ
where vk,Max and vk,min define the maximum and minimum frequency of the considered fre-
quency interval, and R is the resolution used during MRS acquisition. At each iteration, the
software updates the input parameters (i.e. am, φm, c0 . . . c4, Δωm and T2m) and recalculates
the total simulated spectrum using Eq (A3). After 900 iterations the optimization is stopped.
The optimized simulated spectrum, its parameters (am, φm, c0 . . . c4, Δωm and and T2m), and
a graphical comparison between the simulated and acquired spectra (together with their abso-
lute difference) are given as output results.
During the iteration process, the cost function is minimized by using a fixed step gradient
descent algorithm (FSGD). This algorithm belongs to the family of Gradient descent methods
(GD), a common iterative minimization approach which uses the gradient of a cost function
to move across the parameter space to reach a minimum. It is a common choice to search min-
ima inside parameter spaces with several dimensions. Generally, FSGD algorithm updates the
parameters vector using the normalized gradient of the cost function in order to avoid diver-
gences:
paramlþ1ðkÞ ¼ paramlðkÞ  
GðkÞl
jGðkÞlj
dparamlðkÞ ðA6Þ
paraml+1 is the vector containing the parameters at iteration l+1 where the parameters are: am,
φm, c0 . . . c4, Δωm and T2m (m = 1,. . .,3). Besides paraml(k) is the kth component of the vector
paraml at iteration l. Gl is the cost function gradient at iteration l and G(k)l is its kth compo-
nent.
Gl ¼
@costl
@am
;
@costl
@φm
;
@costl
@Dom
;
@costl
@Tm
2
; . . .
 
m ¼ 1; . . . 3 ðA7Þ
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In this approach, only the sign of the kth component of the gradient is used, while the step
of the descent is “preconditioned” by the step vector dparaml. Components of the step vector
were chosen empirically and some of them change their values during the iteration. For exam-
ple, step parameters related to polynomial baseline are constant and are chosen to produce
very weak changes in the spectrum. Phase and shift step parameters are static too, while the
ones related to T
2
decays and amplitudes of metabolites are updated at each iteration, since
they are set to be a fixed ratio of their corresponding parameters. For example, the step vector
for amplitude is chosen to be a 0.5% of the value found after the grid search and it is rescaled at
each iteration:
dalþ1 ¼
al
200
ðA8Þ
At the end of optimization, the amplitudes (and the integrals) are corrected in order to take
account of different metabolite T2 values:
acorrm ¼
am  e
TE
Tm
2
aw
2
 e
TE
Tw
2
ðA9Þ
Where TE is the sequence echo time, T2
m the transverse relaxation time of the metabolite m,
aw the amplitude of the water signal, T2w the water relaxation time. acorrm are the amplitudes
comparable to concentrations (see Materials and Methods, Results, Tables 1–3, Figs 2–3).
Amplitude of water signals was obtained from spectra without water suppression. This correc-
tion was performed also during the AMARES quantification.
Measuring NMR parameters
Using the exact chemical shift value is not crucial for the quantification because the software is
able to correct small deviations of metabolite chemical shift iteratively Eq (A1). A STEAM
sequence with short echo time (8.6 ms) was used to measure initial Cit chemical shifts and Cit
J-coupling in phantoms. Methylene protons of Cit are representable as a strong-coupled AB
system (a typical AB system is depicted in Fig 6). This strong coupling model was used to esti-
mate the J-coupling constant [37]:
JAB ¼
ðn1   n2Þ þ ðn2   n4Þ
2
ðA10Þ
In Eq (A10) ν1, ν2, ν3 and ν4 are the peak frequencies of Cit quartet. Furthermore, νA and νB
are the frequencies of the Cit hydrogen nuclei. These frequencies can be calculated using the
equations [37]:
d ¼
n1 þ n2 þ n3 þ n4
4
; D ¼
ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
ðn2   n3 þ jABÞ
2
  jAB2
q
ðA11Þ
and finally:
nA ¼
Dþ 2d
2
; nB ¼
2d   D
2
ðA12Þ
Within the experimental uncertainties in the simulation νA = 2.44 ppm, νB = 2.56 ppm
and JAB = 15 Hz were set as input spectral parameters for Cit (results are in S1 Table). These
values were taken by Garcı´a-Martı´n et al. [21], but they are almost equal to the calculated
ones (νA = 2.44 ppm, νB = 2.57, and J = 16 Hz). To obtain a faster execution, Cho methyl
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proton was simulated as a single peak centered at 3.12 ppm while Cr methyl resonance was
set to 2.95 ppm (secondary peaks are ignored, while amplitude and area values are rescaled at
the end of the iteration process for their real multiplicity). Due to the poor SNR of STEAM,
In vivo parameters of Cit were estimated using a PRESS sequence with an echo time of 140
ms, chemical shifts and J-coupling were then measured with the method used in phantoms
(S2 Table).
Although the uncertainties are quite big, due to the poor SNR, the values in S2 Table are
agreement with the results of Garcı´a-Martı´n et al. [21]. For the simulations we used νA =
2.602 ppm, νB = 2.708 ppm and JAB = 16.8 Hz for Cit. Cho methyl proton was simulated as a
single peak centered at 3.29 ppm while Cr methyl resonance was set to 3.1 ppm.
Measuring T2 decay constants. Estimation of the T2
m decay parameters was performed
by acquiring phantom n˚5 with PRESS sequences, using a TR of 3000 ms and echo times of
140, 400, 600, 1000, 1200 and 1500 ms, from a voxel of 2⨯2⨯2.5 cm3. T2 values of water, Cho
and Cr were measured through linear regression between the logarithm of the maximum value
of their peaks and TE. Since sequences based on spin-echo do not refocus the j-coupling evolu-
tion, spectrum of Cit changes dramatically varying the echo time. Consequently, T2 was mea-
sured by using the amplitude estimated with the homemade quantification software. In all
cases, good correlations were found: r2 coefficients were 0.96 for Cit, 0.98 for Cho and 0.94 for
Cr. T2
m measured values in phantoms were 610 ± 60 ms for Cit, 630 ± 40 ms for Cho, 700 ± 70
ms for Cr and 1220 ± 70 ms for water. Linear regression analysis is shown in Fig 7. Uncertain-
ties on T2 values were estimated from linear regression analysis and were propagated on the
values of the (Cho+Cr)/Cit ratios in Table 3.
Fig 6. Methylene protons of Cit are a strong-coupled spin system.
doi:10.1371/journal.pone.0165730.g006
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Supporting Information
S1 File. “How_to_compile.txt”. Text file that contains the instructions to compile the source
code “ProstateBuster.cpp” together with a list of the packages needed to install the program
and the instructions to download and compile them.
(TXT)
S2 File. “ProstateBuster.cpp”. This is the source code of the software.
(CPP)
S3 File. “readme.txt”. Text file that contains some usage tips to run the program “ProstateBus-
ter” and test it on the examples contained in the folders.
(TXT)
S4 File. “Software_data.zip”. This is the working directory that should be copied on the user’s
home folder to install and run the program (by following the instructions in “How_to_com-
pile.txt”). It contains a copy of all the previously cited files (“How_to_compile.txt”, “Prosta-
teBuster.cpp” and “readme.txt”) and some raw data examples to test “ProstateBuster”
program.
(ZIP)
S1 Table. Estimated spectral parameters of Cit inside phantoms.
(DOCX)
S2 Table. Estimated spectral parameters of in vivo Cit.
(DOCX)
Fig 7. Linear regression analysis used to estimate the T2 parameters.
doi:10.1371/journal.pone.0165730.g007
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